Clinical Trial

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated September 11, 2023 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced PD-1 inhibitors.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06031636
Lead Sponsor Tianjin Medical University Second Hospital
Conditions Malignant Pleural Mesothelioma, Advanced
Enrollment 15 participants
Start Date 2023-07-20
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2023-09-11